Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin J. van den Bent, Vassilis Golfinopoulos, Juan Manuel Sepúlveda-Sánchez et al.|Neuro-Oncology|2020

Cited by 8